» Articles » PMID: 11234876

The Toxicity of Deglycosylated Ricin A Chain-containing Immunotoxins in Patients with Non-Hodgkin's Lymphoma is Exacerbated by Prior Radiotherapy: a Retrospective Analysis of Patients in Five Clinical Trials

Overview
Journal Clin Cancer Res
Specialty Oncology
Date 2001 Mar 10
PMID 11234876
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

A retrospective analysis of 102 patients with relapsed, non-Hodgkin's lymphoma treated with two different ricin A chain-containing immunotoxins (ITs) in five Phase I clinical trials indicates that the dose-limiting toxicity, vascular leak syndrome, was more frequent and more severe in patients who had undergone prior radiotherapy (RT). Excluding patients with prior RT from the calculations of the maximum tolerated dose indicates that the maximum tolerated doses of these ITs had not been reached in any trial and are clearly higher than reported previously. Excluding patients with prior RT from future clinical trials may increase the dose of ITs that can be given in the absence of severe vascular leak syndrome.

Citing Articles

Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease.

Groth C, van Groningen L, Matos T, Bremmers M, Preijers F, Dolstra H Biol Blood Marrow Transplant. 2018; 25(4):712-719.

PMID: 30399420 PMC: 6595479. DOI: 10.1016/j.bbmt.2018.10.020.


Clinical targeting recombinant immunotoxins for cancer therapy.

Li M, Liu Z, Liu X, Hui Q, Lu S, Qu L Onco Targets Ther. 2017; 10:3645-3665.

PMID: 28790855 PMC: 5530862. DOI: 10.2147/OTT.S134584.


Efficient in vivo antitumor effect of an immunotoxin based on ribotoxin α-sarcin in nude mice bearing human colorectal cancer xenografts.

Tome-Amat J, Olombrada M, Ruiz-de-la-Herran J, Perez-Gomez E, Andradas C, Sanchez C Springerplus. 2015; 4:168.

PMID: 25883890 PMC: 4393403. DOI: 10.1186/s40064-015-0943-5.


Advances in anticancer immunotoxin therapy.

Alewine C, Hassan R, Pastan I Oncologist. 2015; 20(2):176-85.

PMID: 25561510 PMC: 4319635. DOI: 10.1634/theoncologist.2014-0358.


Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.

DAvino C, Paciello R, Riccio G, Coppola C, Coppola M, Laccetti P Protein Eng Des Sel. 2014; 27(3):83-8.

PMID: 24421342 PMC: 3925340. DOI: 10.1093/protein/gzt065.